Tidal Investments LLC Sells 6,827 Shares of Glaukos Co. (NYSE:GKOS)

Tidal Investments LLC trimmed its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 45.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,081 shares of the medical instruments supplier's stock after selling 6,827 shares during the quarter. Tidal Investments LLC's holdings in Glaukos were worth $1,212,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Rhumbline Advisers increased its holdings in Glaukos by 0.3% during the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier's stock worth $21,260,000 after buying an additional 403 shares during the last quarter. IFP Advisors Inc bought a new stake in shares of Glaukos in the 4th quarter valued at about $43,000. US Bancorp DE lifted its stake in Glaukos by 8.3% in the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier's stock valued at $914,000 after purchasing an additional 470 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in Glaukos in the 4th quarter valued at about $227,000. Finally, Raymond James Financial Inc. bought a new position in Glaukos during the fourth quarter worth about $16,910,000. 99.04% of the stock is owned by institutional investors.

Glaukos Price Performance

Shares of GKOS traded down $1.37 during midday trading on Friday, reaching $93.50. The stock had a trading volume of 396,458 shares, compared to its average volume of 703,259. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.34 billion, a price-to-earnings ratio of -32.64 and a beta of 0.83. The company's 50-day moving average is $92.86 and its 200 day moving average is $123.50. Glaukos Co. has a 12-month low of $77.10 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. During the same period last year, the firm earned ($0.70) earnings per share. The company's revenue for the quarter was up 24.6% compared to the same quarter last year. On average, equities analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Truist Financial reissued a "buy" rating and issued a $135.00 price objective (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Morgan Stanley decreased their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Stephens cut their price objective on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company cut Glaukos from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $160.00 to $86.00 in a report on Thursday, May 1st. Finally, Piper Sandler lowered their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Glaukos presently has an average rating of "Moderate Buy" and an average price target of $134.67.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.40% of the stock is currently owned by company insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.